Bayer Will Continue To Develop Repinotan Despite Cutting Stroke Research
Bayer plans to continue Phase III development of stroke drug repinotan despite terminating research on other stroke candidates.
You may also be interested in...
Bayer will use a loading dose of the stroke drug repinotan in Phase III trials following discussions with FDA over how best to maximize treatment response, agency documents show
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011